Mesothelioma Treatment
Mesothelioma Cancer
- Causes of Mesothelioma
- Mesothelioma Symptoms
- Mesothelioma Diagnosis
- Mesothelioma Stages
- Mesothelioma Treatment
- Innovative Mesothelioma Treatments
- Managing Mesothelioma Pain
- Nutrition Information for Mesothelioma Patients
- Specialized Mesothelioma Care
- Mesothelioma Risks
- Mesothelioma Support Groups
- Find a Mesothelioma Attorney
- Mesothelioma News
Mesothelioma Directory
An Efficacy Study of MORAb-009 Amatuximab in Subjects With Pleural Mesothelioma
Get Help Today
Looking for help or additional information? Contact us today.| Conditions: | Malignant Pleural Mesothelioma |
| Start Date: | December 1, 2008 |
| Phase: | Phase II |
| Status: | Recruiting |
| NCT ID: | NCT00738582 |
| Study Type: | Interventional |
| Intervention: | Drug: MORAb-009 Amatuximab by IV on Days 1 and 8 every 21 days for 6 cycles. |
| Study Design: | Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | Morphotek |
| Ages: | Adult|Senior |
| Enrollment: | 86 |
| Funded By: | Industry |
| First Received: | August 19, 2008 |
| End Date: | March 1, 2012 |
| Last Updated: | September 21, 2010 |
| Last Verified: | September 1, 2010 |